Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Panoramica dello studio

Descrizione dettagliata

Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.

Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.

Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.

This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Quebec
      • Montreal, Quebec, Canada, H2X 3E4
        • Santé Québec - Centre hospitalier de l'Université de Montréal
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Stephan Williams, MD, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 90 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age between 18 and 90 years old
  • ASA status I to III inclusively
  • Planned lower body surgery under spinal anesthesia with chloroprocaine
  • Signed informed consent form

Exclusion Criteria:

  • Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
  • Preexisting neuropathy or nerve block that could interfere with study assessments
  • Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
  • Preoperative use of corticosteroids
  • Patient refusal
  • Inability to consent
  • Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
  • Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
  • Perioperative intravenous dexmedetomidine administration
  • Conversion to general anesthesia
  • Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
  • Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Intravenous dexamethasone

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine

Altri nomi:
  • Decadrone
Comparatore placebo: Intravenous normal saline

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine

Altri nomi:
  • Placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Regression of sensory block by 2 dermatomes
Lasso di tempo: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level

At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Duration of motor block
Lasso di tempo: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Time until the first observable regression of the motor block
Lasso di tempo: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale.

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Onset of sensory block
Lasso di tempo: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation

Up to 30 minutes following spinal anesthesia
Onset of motor block
Lasso di tempo: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale

Up to 30 minutes following spinal anesthesia
Quality of motor block
Lasso di tempo: Up to 30 minutes following spinal anesthesia

Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block.

The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block.

Up to 30 minutes following spinal anesthesia
Opioid consumption
Lasso di tempo: At recovery room discharge, approximately one hour after the end of surgery

Total dose of opioids

At recovery room discharge, approximately one hour after the end of surgery
Antiemetic consumption
Lasso di tempo: At recovery room discharge, approximately one hour after the end of surgery

Total dose of antiemetics

At recovery room discharge, approximately one hour after the end of surgery
Incidence of hypotension
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Systolic blood pressure lower than 90 mm Hg

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of bradycardia
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Heart rate slower than 50 beats per minute

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of nausea
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of nausea reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of vomiting
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of retching or vomiting reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of itching
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of itching reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of urinary retention
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of urinary retention reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of shivering
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of shivering reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of headache
Lasso di tempo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of headache reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Quality of postoperative recovery
Lasso di tempo: At 24 hours after the surgery

QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome).

At 24 hours after the surgery
Intensity of nausea/vomiting
Lasso di tempo: At 24 hours after surgery

Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Pain intensity
Lasso di tempo: At 24 hours after surgery

Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Quality of sleep
Lasso di tempo: At 24 hours after surgery

Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Surgeon's satisfaction towards spinal anesthesia
Lasso di tempo: At the end of surgery, on the day of randomization

Unsatisfied or satisfied

At the end of surgery, on the day of randomization

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Stephan Williams, MD, PhD, Santé Québec - CHUM

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 novembre 2027

Date di iscrizione allo studio

Primo inviato

18 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

18 settembre 2026

Primo Inserito (Effettivo)

23 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi